BTOG 2021: KRAS targeting and oncogenically-driven lung cancer

Traditional treatments for lung cancer include chemotherapy, radiotherapy and surgery, however the identification of oncogenic drivers, such as EGFR, ALK and ROS1, offers the potential for novel targeted therapies and personalized approaches to lung cancer treatment. Numerous studies and trials are underway which are investigating therapies targeting oncogenes including KRAS, PD-1/PD-L1 and JAK2, however, targeting of these genes and pathways has presented many challenges. In this podcast Colin Lindsay, BSc, MBChB, MRCP, PhD, of the Christie NHS Foundation Trust, Manchester, UK, and Samreen Ahmed, FRCP, MD, of University Hospitals of Leicester, Leicester, UK, discuss the history of KRAS-targeting and the latest updates in the treatment of oncogenically-driven lung cancer, as presented at the British Thoracic Oncology Group’s 19th Annual Conference, which took place virtually.